Beta-adrenergic drugs and risk of Parkinson’s disease: A
systematic review and meta-analysis

J 2022

Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis

SINGH, Ambrish, Mohammad Salman HUSSAIN, Sreelatha AKKALA, Jitka KLUGAROVÁ, Andrea POKORNÁ et. al.

Basic information

Original name

Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis

Authors

SINGH, Ambrish, Mohammad Salman HUSSAIN (356 India, belonging to the institution), Sreelatha AKKALA, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Miloslav KLUGAR (203 Czech Republic, belonging to the institution), E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR and Benny ANTONY (guarantor)

Edition

AGEING RESEARCH REVIEWS, CLARE, ELSEVIER IRELAND LTD, 2022, 1568-1637

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 13.100

RIV identification code

RIV/00216224:14110/22:00127142

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.arr.2022.101670

UT WoS

000841188700006

Keywords in English

Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease

Abstract

V originále

Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.

Links

EF18_053/0016952, research and development project

Name: Postdoc2MUNI

LTC20031, research and development project

Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

Citovat

SINGH, Ambrish, Mohammad Salman HUSSAIN, Sreelatha AKKALA, Jitka KLUGAROVÁ, Andrea POKORNÁ, Miloslav KLUGAR, E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR and Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. AGEING RESEARCH REVIEWS. CLARE: ELSEVIER IRELAND LTD, 2022, vol. 80, September 2022, p. 1-13. ISSN 1568-1637. Available from: https://dx.doi.org/10.1016/j.arr.2022.101670.

@article{2231684,
   author = {Singh, Ambrish and Hussain, Mohammad Salman and Akkala, Sreelatha and Klugarová, Jitka and Pokorná, Andrea and Klugar, Miloslav and Walters, E. Haydn and Hopper, Ingrid and Campbell, Julie A. and Taylor, Bruce and Antony, Benny},
   article_location = {CLARE},
   article_number = {September 2022},
   doi = {http://dx.doi.org/10.1016/j.arr.2022.101670},
   keywords = {Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease},
   language = {eng},
   issn = {1568-1637},
   journal = {AGEING RESEARCH REVIEWS},
   title = {Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis},
   url = {https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub},
   volume = {80},
   year = {2022}
}

TY  - JOUR
ID  - 2231684
AU  - Singh, Ambrish - Hussain, Mohammad Salman - Akkala, Sreelatha - Klugarová, Jitka - Pokorná, Andrea - Klugar, Miloslav - Walters, E. Haydn - Hopper, Ingrid - Campbell, Julie A. - Taylor, Bruce - Antony, Benny
PY  - 2022
TI  - Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis
JF  - AGEING RESEARCH REVIEWS
VL  - 80
IS  - September 2022
SP  - 1-13
EP  - 1-13
PB  - ELSEVIER IRELAND LTD
SN  - 15681637
KW  - Beta-adrenoceptors
KW  - Beta-blockers
KW  - Beta -antagonist
KW  - Beta-agonist
KW  - Propranolol
KW  - Salbutamol
KW  - Parkinson ?s disease
UR  - https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub
N2  - Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
ER  -

SINGH, Ambrish, Mohammad Salman HUSSAIN, Sreelatha AKKALA, Jitka KLUGAROVÁ, Andrea POKORNÁ, Miloslav KLUGAR, E. Haydn WALTERS, Ingrid HOPPER, Julie A. CAMPBELL, Bruce TAYLOR and Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. \textit{AGEING RESEARCH REVIEWS}. CLARE: ELSEVIER IRELAND LTD, 2022, vol.~80, September 2022, p.~1-13. ISSN~1568-1637. Available from: https://dx.doi.org/10.1016/j.arr.2022.101670.

Detailed Information on Publication Record